# Nanjing Yixi Biotechnology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nanjing-yixi-biotechnology

- Industry: Biotechnology
- Headquarters: Nanjing, China
- Website: www.yixilife.com
- Total disclosed funding: $28M
- Latest round: Series A (Aug 20, 2025)
- Investors on record: 1

## About

Established in 2019 and based in Suzhou, China, Nanjing Yixi Biotechnology is a synthetic biology company focusing on synthetic biology technology innovation and product development. The company has a production plant in Huangshan, Anhui Province, covering an area of 100 acres, with a current capacity of 300 tons/year. In January 2022, the company completed the construction of its R&D center in Suzhou and relocated to the Suzhou Industrial Park. In August 2023, the company closed a round of pre-series A funding. The Company's products mainly include human milk oligosaccharides (HMOs), a synthetic bioproduct that blocks pathogens and promotes the growth of beneficial bacteria, which can be used in probiotics, dietary supplements and other food products. It also has Single Cell Protein (SCP) for feeding, a protein product that uses lignocellulose from straw as a raw material and is fermented by a combination of microorganisms to produce single-cell proteins that can be used as feed for pigs, chickens, cows, sheep and other livestock. The company generates revenue through deployment of its AI diagnostic systems, enterprise healthcare platforms, and service contracts with medical institutions. In August 2025, Nanjing Yixi Biotechnology raised nearly CNY 200 million in Series A funding from new investor Huangshan Xinanjiang Capital Investment Management.

## Funding rounds

- Series A, Aug 20, 2025, $28M — Huangshan Xinanjiang Capital Investment Management

## Investors

- Huangshan Xinanjiang Capital Investment Management (https://capitalatlas.ai/funds/huangshan-xinanjiang-capital-investment-management) — Series A